Press Release

PhRMA Statement on Codes of Conduct

PhRMA April 30, 2013

Washington, D.C. (February 19, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement today regarding the Biotechnology Industry Organization’s position on codes of conduct for interactions with healthcare professionals:

“PhRMA is pleased to hear that the Biotechnology Industry Organization (BIO) is encouraging its member companies to adopt a code of conduct such as PhRMA’s Code on Interactions with Healthcare Professionals.

“Last July, we revised and strengthened our Code as part of our ongoing efforts to purse policies and practices that best serve the needs of patients and the healthcare community. We have since reached out to physician community, professional groups, non-PhRMA member companies and other healthcare stakeholders to explain how the Code has been enhanced to better ensure that pharmaceutical marketing practices comply with the highest ethical standards.

“The feedback we have received has been very positive, and we remain committed to engaging as many stakeholders as possible.

“The voluntary PhRMA Code, which took effect in January 2009, reaffirms that interactions between company representatives and healthcare professionals ‘should be focused on informing the healthcare professionals about products, providing scientific and educational information, and supporting medical research and education.’

“Providing physicians with up-to-date, accurate information about the medicines they prescribe clearly improves patient care and advances health care in general. Pharmaceutical research companies that discover and develop new medicines are the most knowledgeable about their products and are in the best position to inform healthcare professionals about a wide range of topics related to these medicines, including new treatment options, appropriate dosing, emerging safety developments and potential interactions with other drugs.

“Our updated Code fortified our companies’ commitment to ensure their medicines are marketed in a manner that benefits patients and enhances the practice of medicine. It marked a renewed pledge to ‘practice what we preach.’

“To date, over 40 companies – including several non-PhRMA member companies – have committed to abide by the PhRMA Code. We hope all companies that interact with healthcare professionals will adopt these standards.”


The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

PhRMA en Español:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: